A number of other equities research analysts have also recently issued reports on RTRX. BMO Capital Markets decreased their target price on Retrophin from $38.00 to $33.00 and set an outperform rating for the company in a research report on Friday, August 23rd. Leerink Swann set a $35.00 target price on Retrophin and gave the stock a buy rating in a research report on Thursday, August 22nd. JMP Securities set a $26.00 target price on Retrophin and gave the stock a buy rating in a research report on Thursday, August 22nd. ValuEngine raised Retrophin from a hold rating to a buy rating in a research report on Wednesday, October 2nd. Finally, Jefferies Financial Group set a $33.00 target price on Retrophin and gave the stock a buy rating in a research report on Friday, August 23rd. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $27.75.
NASDAQ RTRX traded up $0.03 on Friday, reaching $12.94. The company’s stock had a trading volume of 213,200 shares, compared to its average volume of 412,267. The firm’s 50 day moving average is $11.79 and its two-hundred day moving average is $16.30. Retrophin has a twelve month low of $10.87 and a twelve month high of $26.80. The stock has a market cap of $557.97 million, a PE ratio of -5.09 and a beta of 0.79. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.94 and a current ratio of 5.00.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.55. Retrophin had a negative return on equity of 43.88% and a negative net margin of 71.70%. The firm had revenue of $44.37 million for the quarter, compared to the consensus estimate of $45.31 million. During the same quarter in the prior year, the company posted ($0.68) earnings per share. The firm’s revenue was up 9.0% on a year-over-year basis. Equities research analysts anticipate that Retrophin will post -3.45 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in RTRX. Tower Research Capital LLC TRC bought a new stake in Retrophin during the second quarter worth approximately $26,000. Meeder Asset Management Inc. boosted its position in shares of Retrophin by 641.4% in the third quarter. Meeder Asset Management Inc. now owns 4,011 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 3,470 shares during the period. Cutler Group LP bought a new stake in shares of Retrophin in the third quarter valued at approximately $70,000. Russell Investments Group Ltd. boosted its position in shares of Retrophin by 117.7% in the third quarter. Russell Investments Group Ltd. now owns 24,700 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 13,355 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Retrophin by 19.6% in the second quarter. JPMorgan Chase & Co. now owns 17,172 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 2,815 shares during the period.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Story: Bid-Ask Spread
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.